Tests CM336 in adults with relapsed or refractory multiple myeloma
Tests CM336, a new injection, in adults whose multiple myeloma returned or did not respond.
Plain-language title generated from the registry record
Registry title: A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or did not respond to earlier treatment. It tests a drug called CM336.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Multiple myeloma that came back (relapsed) or did not respond to treatment (refractory). Daily activity level (ECOG) of 0-2.
- Earlier treatment
- At least 2 earlier anti-myeloma treatments, including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody (if available). Earlier treatments failed or were not tolerated.
Main reasons for not taking part
- Earlier BCMA-targeted therapy
- Earlier CAR-T therapy
- Anti-tumor therapy within 3 weeks or 5 half-lives (whichever is shorter) before the first dose of CM336
Read by machine on 9 November 2026.
Where in China
- Peking University Third HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Keymed Biosciences Co.Ltd
- Trial code
- NCT05299424
- Record updated
- 15 October 2024
- Original description
This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma.Read full original descriptionShow less
A Multi-center, Open-label, Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Multiple Myeloma
This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma.
This study consists of a dose escalation part (Phase 1) and a dose extension part (Phase 2 ).
The safety and tolerability of CM336 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined.
The efficacy of CM336 will be evaluated in Phase 2 study.
Inclusion: Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2; Patients with relapsed or refractory MM who have failed or are intolerant to all therapies with known clinical benefit; patients must have received at least 2 prior anti-myeloma therapies which must contain at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38 monoclonal antibody (if available).
Exclusion: Patients who had received BCMA-targeted therapy; Patients who had received CAR-T therapy; Patients who had received anti-tumor therapy within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of CM336.